[go: up one dir, main page]

AU2001256507A1 - Modulation - Google Patents

Modulation

Info

Publication number
AU2001256507A1
AU2001256507A1 AU2001256507A AU5650701A AU2001256507A1 AU 2001256507 A1 AU2001256507 A1 AU 2001256507A1 AU 2001256507 A AU2001256507 A AU 2001256507A AU 5650701 A AU5650701 A AU 5650701A AU 2001256507 A1 AU2001256507 A1 AU 2001256507A1
Authority
AU
Australia
Prior art keywords
modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001256507A
Inventor
Fiona Mclaughlin
Anna Maria Randi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2001256507A1 publication Critical patent/AU2001256507A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2001256507A 2000-05-16 2001-05-15 Modulation Abandoned AU2001256507A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20449300P 2000-05-16 2000-05-16
US60204493 2000-05-16
PCT/GB2001/002140 WO2001088122A2 (en) 2000-05-16 2001-05-15 Erg modulators

Publications (1)

Publication Number Publication Date
AU2001256507A1 true AU2001256507A1 (en) 2001-11-26

Family

ID=22758131

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001256507A Abandoned AU2001256507A1 (en) 2000-05-16 2001-05-15 Modulation

Country Status (2)

Country Link
AU (1) AU2001256507A1 (en)
WO (1) WO2001088122A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001261676A1 (en) * 2000-05-16 2001-11-26 Glaxo Group Limited Method and reagent for the inhibition of erg
JP5009787B2 (en) 2004-05-07 2012-08-22 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド A method for diagnosing or treating prostate cancer using the ERG gene alone or in combination with other genes that are overexpressed or underexpressed in prostate cancer
EP3229821B1 (en) * 2014-12-12 2020-09-23 Tufts University Collagenase-derived peptides promote tissue regeneration and wound healing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1175871A (en) * 1997-06-18 1999-03-23 Chugai Pharmaceut Co Ltd Cell calcification suppressing active protein and gene coding for the same protein
US6054316A (en) * 1999-06-25 2000-04-25 Isis Pharmaceuticals Inc. Antisense inhibition of ETs-2 expression

Also Published As

Publication number Publication date
WO2001088122A3 (en) 2002-04-25
WO2001088122A2 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
AU6419701A (en) Electropancreatography
AU2001262847A1 (en) Language-understanding
AU2002211620A1 (en) Autoanastomosis
AU2000267458A1 (en) Hypercomputer
AU2001220246A1 (en) Neckphone
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001296577A1 (en) Chlorophyllases
AU2001258349A1 (en) Bisacylguanidine
AU2001279754A1 (en) Indoloquinazolinones
AU2002211128A1 (en) Step-bike
AU2001285886A1 (en) 2-guanidino-4-aryl-quinazoline
AU2001258924A1 (en) Microsatellite-aflp
AU2001293852A1 (en) Sulfonylguanidine
AU2002226346A1 (en) 2-aryl-5-trifluoromethylpyridines
AU2001281921A1 (en) Bdellosomes
AU2001291876A1 (en) Triazolo-epothilones
EP1368891B8 (en) Iq modulator
AU2002214354A1 (en) Neck-phone
AU4620300A (en) Can
AU2001262711A1 (en) Cytoprotectors
AU2001284173A1 (en) Calycins
AU2001260192A1 (en) Glycinamides
AU2001256507A1 (en) Modulation
AU5018801A (en) Offside-detection-system
AU2001275014A1 (en) Imidazoloisoquinolines